Immunoactivating Peptide P4 Augments Alveolar Macrophage Phagocytosis in Two Diverse Human Populations

Mathieu Bangert, Adam K. Wright, Jamie Rylance, Matthew J. Kelly, Angela D. Wright, George M. Carlone, Jacquelyn S. Sampson, Gowrisankar Rajam, Edwin W. Ades, Aras Kadioglu and Stephen B. Gordon

Published Ahead of Print 1 July 2013.

Updated information and services can be found at:
http://aac.asm.org/content/57/9/4566

These include:

This article cites 10 articles, 5 of which can be accessed free at:
http://aac.asm.org/content/57/9/4566#ref-list-1

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
Immuoactivating Peptide P4 Augments Alveolar Macrophage Phagocytosis in Two Diverse Human Populations

Mathieu Bangert,a,d Adam K. Wright,a Jamie Rylance,b Matthew J. Kelly,b Angela D. Wright,a George M. Carline,f Jacquelyn S. Sampson,c Gowrisankar Rajam,c Edwin W. Ades,a Aras Kadioglu,d Stephen B. Gordonb

Respiratory Infection Group, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; Malawi-Liverpool-Wellcome Clinical Research Laboratories, Blantyre, Malawi; Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Clinical Infection, Microbiology and Immunology, Institute of Infection & Global Health, University of Liverpool, Liverpool, United Kingdom

New treatment strategies are urgently needed to overcome early mortality in acute bacterial infections. Previous studies have shown that administration of a novel immunoactivating peptide (P4) alongside passive immunotherapy prevents the onset of septicemia and rescues mice from lethal invasive disease models of pneumococcal pneumonia and sepsis. In this study, using two diverse populations of adult volunteers, we determined whether P4 treatment of human alveolar macrophages would upregulate phagocytic killing of Streptococcus pneumoniae ex vivo. We also measured macrophage intracellular oxidation, cytokine secretion, and surface marker expression following stimulation. Peptide treatment showed enhanced bacterial killing in the absence of nonspecific inflammation, consistent with therapeutic potential. This is the first demonstration of P4 efficacy on ex vivo-derived human lung cells.

The rate of early mortality from severe pneumonia and sepsis is high in developed and developing countries. Antibiotic treatment alone is inadequate for severe infections, as treatment has not been shown to reduce deaths that occur in the initial 48-hour period following admission (1). To bridge this treatment window, augmented passive immunotherapy (API) is a potential new treatment paradigm that uses the concurrent administration of an immunoactivating peptide (P4) to enhance phagocytosis with pathogen-specific antibodies in pooled immunoglobulin (IVIG). P4 is a 28-amino-acid (aa) peptide derived from the functional site of the Streptococcus pneumoniae pneumococcal surface adhesion A protein (PsaA) (2). Murine models of acute infection have demonstrated the therapeutic benefits of API administered by either intranasal or intravenous routes. Such treatment has been demonstrated to rescue mice from invasive pneumonia (3, 4), influenza-pneumonia coinfections (5), and methicillin-resistant Staphylococcus aureus (MRSA) (6), independent of age (7) and strain background (8), although to date there are no data from human lung samples. Since P4 peptide treatment of Streptococcus pneumoniae (pneumococcus)-infected murine lungs prevented the onset of sepsis and subsequent host mortality (4), we hypothesized that ex vivo P4 treatment of human alveolar macrophages would lead to enhanced phagocytic function with no or limited generalization inflammation.

To test this hypothesis, healthy adult volunteers were recruited to a study in Liverpool (United Kingdom) and Blantyre (Malawi) involving bronchoscopy and bronchoalveolar lavage (BAL). Ethical approval was obtained from the National Health Service Research Ethics Committee (11/NW/0011) and the Malawi College of Medicine Ethics Committee (P.03/11/1063). The median age of United Kingdom volunteers was 25.6 years ± 9.5 (8 females, 6 males) and that of Malawian volunteers was 31.4 years ± 3.3 (11 females, 2 males). Alveolar macrophages were isolated from BAL fluid collected during bronchoscopy by adherence and washing steps, resulting in >95% alveolar macrophage purity. An opsonophagocytosis killing assay (OPKA) was then performed as previously described (3) with minor modifications. Briefly, 1 × 10^5 macrophages were allowed to phagocytose IVIG-opsonized Streptococcus pneumoniae strain D39-ST2 (IVIG final dilution, 1:32; multiplicity of infection, 1:100) in the presence of complement for 2 h. P4 peptide solution (10 μl of 1 mg/ml solution) was added to the OPKA mixture following the preopsonization stage, and CFU were cultured from supernatants following a 2-h incubation. A bacterial killing index was established by comparing the number of pneumococci recovered after OPKA to the number of pneumococci added. In some reactions, Fcy receptors were occupied using human IgG prior to OPKAs to assess the involvement of Fcy receptors during P4-augmented phagocytosis. In line with previous data on murine macrophages (4), peptide stimulation of human alveolar macrophages led to significantly enhanced bacterial killing in both the United Kingdom (40.1% killing for control versus 68.2% killing for P4 treated; P < 0.001, analysis of variance [ANOVA]; n = 14 volunteers) and Malawian (35.8% killing for control versus 47.6% for P4 treated; P < 0.01, ANOVA; n = 13 volunteers) populations (Fig. 1A). In contrast, phagocytosis in the absence of antibody or complement was reduced to 10.8% or 20.1%, respectively, and no detectable differences between stimulated and nonstimulated groups were seen (n = 6; United Kingdom population). Similarly, macrophages in which Fcy receptors were occupied following stimulation showed reduced phagocytosis (23.3%), and no detectable differences between stimulated and nonstimulated groups were seen (Fig. 1B). There is therefore a necessity for all components involved in phagocytosis (immunoglobulin, ...
complement, phagocytic receptors) to be present for P4 treatment to be effective.

Alveolar macrophages respond to stimuli and infection with increased oxidative metabolism. We assessed whether peptide treatment would alter intracellular oxidation in the presence and absence of immune complexes using a technique previously described (9). Briefly, alveolar macrophages were first incubated with 2',7'-dichlorofluorescein-diacetate (DCFH-DA), followed by lipopolysaccharide (LPS) (100 μg/ml solution; Sigma, United Kingdom) or P4 solution (10 μl of 1 mg/ml solution). Intracellular oxidation was then measured using a microplate reader (BMG Labtech, United Kingdom). The assay was also performed with opsonized pneumococci to measure intracellular oxidation in response to P4-mediated phagocytosis. P4 treatment of alveolar macrophages exposed to opsonized bacteria and complement (n = 6; United Kingdom population) led to a significant increase

**FIG 1** (A) Opsonophagocytosis killing assay (OPKA) using human alveolar macrophages from healthy volunteers recruited in Liverpool, United Kingdom (n = 14), and Blantyre, Malawi (n = 13); (B) OPKA of United Kingdom volunteers (n = 6), where “OPK” designates assays in which all components are included (macrophage, bacteria, antibody, complement), “no antibody” designates assays without the presence of antibody, “no complement” designates assays without the presence of complement, and “FcγR block” designates assays where Fcγ receptors were occupied by IgG prior to the assay; (C) intracellular oxidation of alveolar macrophages (n = 6; United Kingdom population) during an opsonophagocytosis assay in the presence (OPKA+P4) or absence (OPK) of peptide stimulation; (D) intracellular oxidation in the presence of PBS, LPS (100 μg/ml), or P4 (1 mg/ml) alone; (E) cytokine levels detected in OPKA supernatant using a BD Flex Set kit following a 2-h OPKA; (F) surface markers of activation on control or P4-activated alveolar macrophages (n = 6) following a 2-h OPKA, stained and analyzed using flow cytometry.
in Malawi, disease incidence is significantly higher, due to greater exposure and risk factors, including malnutrition, smoke exposure, and concurrent infections (10).

In summary, we have shown that P4 peptide treatment of human alveolar macrophages led to a significant increase in their ability to phagocytose opsonized pneumococci. Importantly, we show P4 efficacy in two diverse human populations with differing levels of susceptibility to pneumococcal disease. These data are consistent with rescue from pneumonia and sepsis, as demonstrated in murine models. Our findings are important, as early treatment options for severe sepsis are urgently needed, and API offers a new paradigm for treatment of invasive diseases such as sepsis. As API is an antibody-driven treatment, in the presence of effective opsonization, peptide stimulation will lead to enhanced phagocytosis irrespective of the pathogen. Opsonization occurs through the broad specificity of IVIG, and the formed immune complexes are effectively cleared through the effects of peptide stimulation (including modulation of phagocytic Fcγ receptors) on phagocytes (4, 5). This has the potential to rapidly assist an infected patient prior to diagnostic results and antibiotic efficacy. We envisage P4 and immunoglobulin administration as part of an adjunct therapy with antibiotic treatment, a strategy that has previously been shown to rescue mice with lethal invasive pneumonia (8).

To our knowledge, this is the first demonstration of exogenous peptide treatment leading to increased opsonophagocytosis of bacteria by human alveolar macrophages. Together with our previous studies, we have now shown that P4 therapy is highly effective in stimulating major phagocytes involved in defending against pneumonia and sepsis in both in vitro human and in vivo murine studies. Augmented passive immunotherapy is a promising new strategy for clinical testing within a broad range of patient groups suffering from respiratory infections.

ACKNOWLEDGMENTS

This work was funded by a Crossley Barnes Scholarship (University of Liverpool) to M.B., the NIHR Biomedical Research Centre in Microbial Diseases to A.K.W., and a Wellcome Trust Clinical Fellowship to J.R.

We thank the MLW for support, Daniel R. Neill for critical reading of the manuscript, and all the volunteers for participation.

REFERENCES

7. Rajam G, Bangert M, Hammons GM, Melnick N, Carlone GM, Samp-

